| Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ... Nature medicine 23 (6), 703-713, 2017 | 3254 | 2017 |
| Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children A Drilon, TW Laetsch, S Kummar, SG DuBois, UN Lassen, GD Demetri, ... New England Journal of Medicine 378 (8), 731-739, 2018 | 2777 | 2018 |
| OncoKB: a precision oncology knowledge base D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ... JCO precision oncology 1, 1-16, 2017 | 2379 | 2017 |
| A view on drug resistance in cancer N Vasan, J Baselga, DM Hyman Nature 575 (7782), 299-309, 2019 | 2263 | 2019 |
| Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations DM Hyman, I Puzanov, V Subbiah, JE Faris, I Chau, JY Blay, J Wolf, ... New England Journal of Medicine 373 (8), 726-736, 2015 | 1996 | 2015 |
| AACR Project GENIE: powering precision medicine through an international consortium AACR Project Genie Consortium, AACR Project GENIE Consortium, ... Cancer discovery 7 (8), 818-831, 2017 | 1494 | 2017 |
| Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy D Chowell, LGT Morris, CM Grigg, JK Weber, RM Samstein, V Makarov, ... Science 359 (6375), 582-587, 2018 | 1105 | 2018 |
| Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials DS Hong, SG DuBois, S Kummar, AF Farago, CM Albert, KS Rohrberg, ... The Lancet Oncology 21 (4), 531-540, 2020 | 941 | 2020 |
| The genomic landscape of endocrine-resistant advanced breast cancers P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ... Cancer cell 34 (3), 427-438. e6, 2018 | 919 | 2018 |
| Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes CC Coombs, A Zehir, SM Devlin, A Kishtagari, A Syed, P Jonsson, ... Cell stem cell 21 (3), 374-382. e4, 2017 | 783 | 2017 |
| Clinical sequencing defines the genomic landscape of metastatic colorectal cancer R Yaeger, WK Chatila, MD Lipsyc, JF Hechtman, A Cercek, ... Cancer cell 33 (1), 125-136. e3, 2018 | 779 | 2018 |
| HER kinase inhibition in patients with HER2-and HER3-mutant cancers DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ... Nature 554 (7691), 189-194, 2018 | 761 | 2018 |
| Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies EJ Jordan, HR Kim, ME Arcila, D Barron, D Chakravarty, JJ Gao, ... Cancer discovery 7 (6), 596-609, 2017 | 643 | 2017 |
| Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease EL Diamond, L Dagna, DM Hyman, G Cavalli, F Janku, J Estrada-Veras, ... Blood, The Journal of the American Society of Hematology 124 (4), 483-492, 2014 | 632 | 2014 |
| High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants P Razavi, BT Li, DN Brown, B Jung, E Hubbell, R Shen, W Abida, K Juluru, ... Nature medicine 25 (12), 1928-1937, 2019 | 626 | 2019 |
| Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer A Latham, P Srinivasan, Y Kemel, J Shia, C Bandlamudi, D Mandelker, ... Journal of clinical oncology 37 (4), 286-295, 2019 | 592 | 2019 |
| Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making W Abida, J Armenia, A Gopalan, R Brennan, M Walsh, D Barron, D Danila, ... JCO precision oncology 1, 1-16, 2017 | 585 | 2017 |
| Genome doubling shapes the evolution and prognosis of advanced cancers CM Bielski, A Zehir, AV Penson, MTA Donoghue, W Chatila, J Armenia, ... Nature genetics 50 (8), 1189-1195, 2018 | 577 | 2018 |
| Cancer therapy shapes the fitness landscape of clonal hematopoiesis KL Bolton, RN Ptashkin, T Gao, L Braunstein, SM Devlin, D Kelly, M Patel, ... Nature genetics 52 (11), 1219-1226, 2020 | 567 | 2020 |
| Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial BT Li, R Shen, D Buonocore, ZT Olah, A Ni, MS Ginsberg, GA Ulaner, ... Journal of Clinical Oncology 36 (24), 2532-2537, 2018 | 551 | 2018 |
David SolitCo-Director, Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer CenterVerified email at mskcc.org